DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation

Table 3 OS in DLBCL treated by RCHOP-like regime

	OS	p_value	OS	p_value
	HR_U(95%CI)	p_value	HR_M(95%CI)	p_value
Age
< 60	1
≥ 60	3.449 (1.177–10.102)	0.024*
BM
Negative	1
Positive	0.918 (0.121–6.985)	0.934
Site
Extranodal	1
Nodal	0.736 (0.267–2.029)	0.553
IHC Hans’ algorithm
GCB	1
Non-GCB	0.935 (0.320–2.738)	0.903
MYC FISH Breakapart
Negative	1
Positive	2.226 (0.291–17.011)	0.440
IPI risk category
Low	1		1
Low_intermediate	1.438 (0.263–7.853)	0.675	0.955 (0.171–5.797)	0.996
High_intermediate	6.223 (1.540–25.147)	0.010	4.342 (1.031–18.297)	0.045
High	7.006 (1.875–26.184)	0.004	12.955 (2.946–56.971)	0.001
Therapy
RCHOP	1
Resection & RCHOP	0.378 (0.085–1.674)	0.200
CNA_based_cluster
Cluster_1	1
Cluster_2	5.432 (1.426–20.695)	0.013
Cluster_3	0.821 (0.222–3.032)	0.767
Three subgroups of DLBCL
DLBCL_others	1		1
DLBCL_JAK2/PD-L2_amp	8.361 (2.093–33.394)	0.003	9.558 (1.921–47.560)	0.006
DLBCL_MYD88_L265P	3.732 (1.177–11.830)	0.025	7.706 (1.838–32.314)	0.005

HR_U hazard ratio by univariate analysis, HR_M hazard ratio by multivariate analysis
* Because age was contained in the IPI, thus it wasn’t put into multivariate analysis

ISSN: 1471-2407